Roivant Sciences

Roivant aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter

[Roivant Sciences @Roivant]

Didn't catch our #JPM26 presentation? Catch the video we presented here

"Either you were in the M&A basket and public markets investors thought you were going to get bought by Big Pharma and your stock traded well, or you weren't...[but] it's great to be in an environment where we have another path forward as a business"

[BiotechTV @BiotechTV]

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: Two CEOs who are so unfiltered, even we had to censor them at times. Watch the full discussion with @Roivant CEO @gline and @BridgeBioPharma CEO Neil Kumar on BiotechTV.

Link: https://t.co/LQLglZ4EKP

[Roivant Sciences @Roivant]

https://t.co/d2PSyQBylK

[Roivant Sciences @Roivant]

📽️📽️📽️Tune in for an honest, unscripted conversation with @gline and @BridgeBioPharma's CEO Neil Kumar. This was a fun one! Thank you @bradloncar and @BiotechTV + Spotify link below ⬇️

[BiotechTV @BiotechTV]

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: @BridgeBioPharma Founder & CEO Neil Kumar and @Roivant CEO @gline discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term. $BBIO $ROIV

Watch the full episode: https://t.co/LQLglZ4EKP

[Roivant Sciences @Roivant]

We're really excited to share this one with @BridgeBioPharma's CEO Neil Kumar. Was a great discussion -- catch it on @biotechtv tomorrow AM!

[BiotechTV @BiotechTV]

𝐃𝐫𝐨𝐩𝐩𝐢𝐧𝐠 𝐭𝐨𝐦𝐨𝐫𝐫𝐨𝐰: In a new episode of Off-Target Effects with @gline, Matt speaks with @BridgeBioPharma CEO Neil Kumar. It will be out tomorrow at 8:00AM ET. Not to be missed!

[Roivant Sciences @Roivant]

Don’t miss it — @gline interviews @JMaraganore in the video below. Thanks to @bradloncar and @BiotechTV for the platform!

[BiotechTV @BiotechTV]

𝐎𝐟𝐟-𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: @JMaraganore has been a champion of innovation throughout his career. He and @gline discuss the road to success at @Alnylam, today's environment, and keeping the U.S. on top.

Watch the episode: https://t.co/AtVmcj7Tou

[Roivant Sciences @Roivant]

Don’t miss this discussion with @gline and @JMaraganore — going live tomorrow!

[BiotechTV @BiotechTV]

𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰: Catch a new episode of Off-Target Effects with @gline on BiotechTV. Matt's guest will be @JMaraganore - it is a great discussion that you don't want to miss. Will drop at 8:00AM ET tomorrow!

[Roivant Sciences @Roivant]

@jeremyj0916 Yeah, fair

[Roivant Sciences @Roivant]

Didn't catch our #JPM26 presentation? Catch the video we presented here

"Either you were in the M&A basket and public markets investors thought you were going to get bought by Big Pharma and your stock traded well, or you weren't...[but] it's great to be in an environment where we have another path forward as a business"

[Roivant Sciences @Roivant]

Until you had this opportunity for companies to "graduate", what it felt like to be a public biopharma CEO...either you were in the M&A basket and public markets investors thought you were going to get bought by Big Pharma and your stock traded well, or you weren't... [but] *it's great to be in an environment where we have another path forward as a business*

Watch the clip from @gline's presentation at #JPM26 #JPM2026

https://t.co/oXWlUiRX8u

[Roivant Sciences @Roivant]

Join us at @jpmorgan's 44th Annual Healthcare Conference where our CEO @gline will take center stage to discuss Roivant’s strong track record, upcoming developments and what’s ahead in 2026 and beyond. #JPM2026

[Roivant Sciences @Roivant]

Curious about how we’re continuing to evolve at Roivant? Check out the @Biotech2050Pod featuring our CEO, @gline, to learn how we're approaching development: https://t.co/UaP2EbCUk5

[Roivant Sciences @Roivant]

We had a packed house for our recent Investor Day where we highlighted continued pipeline progress and our outlook for the next phase of growth while maintaining our unique culture, dynamism and focus on shareholder value creation. Review our presentation: https://t.co/mOBWcA4kl6

[Daniel S. Levine @dslevine]

Ben Zimmer @priovanttx discusses the company's experimental targeted therapy to treat the rare autoimmune condition dermatomyositis and how its relationship with its parent @Roivant frees it from reliance on the capital markets. @GlobalGenes #RARECast

https://t.co/vxYI3Rmbof

[Roivant Sciences @Roivant]

Uncontrolled Graves’ disease can lead to serious health complications including eye inflammation and swollen, bulging eyes. We believe in FcRN-targeted therapies that may help reframe care for people living with Graves’ disease. Learn more: https://t.co/GP8xSz96Ru #GravesDisease

[BiotechTV @BiotechTV]

𝐉𝐞𝐟𝐟𝐞𝐫𝐢𝐞𝐬 𝐋𝐨𝐧𝐝𝐨𝐧: Catching up with @Roivant CEO @gline at the @Jefferies Global Healthcare Conference in London. $ROIV

[Roivant Sciences @Roivant]

Today, we reported our Q2 financial results. Find key highlights here: https://t.co/Nk5KU34kHb

[Roivant Sciences @Roivant]

We were honored with the Double Helix Award at @LS_Cares’ Impact Night! Thank you Life Science Cares New York for helping us be on the frontlines making a difference for patients and communities in need.

[Roivant Sciences @Roivant]

Graves’ disease, an autoimmune disease, disproportionately impacts women. Learn how Immunovant is applying a patient-focused approach to help advance treatment for people living with this condition: https://t.co/UecNjdjQ1v #GravesDisease